0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
ARTICLE |

Mealtime Treatment With Insulin Analog Improves Postprandial Hyperglycemia and Hypoglycemia in Patients With Non-Insulin-Dependent Diabetes Mellitus

James H. Anderson Jr, MD; Rocco L. Brunelle, MS; Patrick Keohane, MD; Veikko A. Koivisto, MD; Michael E. Trautmann, MD; Louis Vignati, MD; Richard DiMarchi, PhD
Arch Intern Med. 1997;157(11):1249-1255. doi:10.1001/archinte.1997.00440320157015.
Text Size: A A A
Published online

Background:  Insulin lispro is an insulin analog that was recently developed particularly for a mealtime therapy. It has a fast absorption rate and short duration of action. The efficacy of insulin lispro in the clinical therapy of patients with non-insulin-dependent diabetes mellitus (NIDDM) has not been tested.

Objectives:  To compare insulin lispro and human regular insulin in the mealtime treatment of patients with NIDDM.

Methods:  A 6-month, randomized, multinational (16 countries), multicenter (80 sites) clinical trial with an open-label, crossover design was performed in 722 patients with NIDDM. Insulin lispro was injected immediately before and human regular insulin 30 to 45 minutes before the meal.

Results:  Throughout the study, the postprandial rise in serum glucose levels was significantly lower during insulin lispro than human regular insulin treatment. At end point the rise (mean ± SEM) in serum glucose levels was 30% lower at 1 hour (2.6±0.1 mmol/L [46.8±1.8 mg/ dL] for lispro vs 3.7±0.1 mmol/L [66.6±1.8 mg/dL] for human regular insulin) and 53% lower 2 hours after the test meal (1.4±0.1 mmol/L [25.2±1.8 mg/dL] for lispro vs 3.0±0.1 mmol/L [54.0±1.8 mg/dL] for human regular insulin) with insulin lispro compared with human regular insulin therapy (P<.001 for both intervals). During insulin lispro therapy the rate of hypoglycemia overall (P=.01) and overnight (P<.001) was lower and the number of asymptomatic hypoglycemic episodes was smaller (P=.03) than during human regular insulin therapy. Associated with a similar 13% increase (P<.001) in the total daily insulin dose, the glycosylated hemoglobin level decreased (P<.001) equally in both treatment groups. Serum lipid and lipoprotein levels remained unchanged. There were no differences in the adverse events between the 2 treatment groups.

Conclusions:  Compared with human regular insulin therapy, mealtime therapy with insulin lispro reduced postprandial hyperglycemia and may decrease the rate of mild hypoglycemic episodes in patients with NIDDM.Arch Intern Med. 1997;157:1249-1255

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Figures

Tables

References

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 148

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();